The Motley Fool··Rich SmithLenz Therapeutics Stock Crashes 11.2% on Missed Earnings and Weak VIZZ Launch
Lenz Therapeutics stock plummeted 11.2% after Q4 earnings miss, larger-than-expected losses, and disappointing VIZZ prescription uptake despite strong pipeline projections.
LENZstock declineearnings miss